Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,923 | -8,153 | -13,518 | -24,427 | -24,502 |
| Depreciation Amortization | 685 | 685 | 687 | 684 | 684 |
| Accounts payable and accrued liabilities | -2,186 | 42 | 1,799 | 33 | 1,447 |
| Other Working Capital | -47 | 2,183 | 2,483 | -1,756 | 4,030 |
| Other Operating Activity | 2,280 | 39 | -1,799 | 3,530 | 931 |
| Operating Cash Flow | $-6,190 | $-5,205 | $-10,348 | $-21,937 | $-17,410 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -30 | N/A | -6 |
| Investing Cash Flow | $N/A | $N/A | $-30 | $N/A | $-6 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 50 | N/A | N/A | N/A | N/A |
| Debt Issued | 6,435 | 4,476 | 9,306 | N/A | N/A |
| Common Stock Issued | 269 | 674 | 13 | 3,635 | 14,204 |
| Other Financing Activity | 0 | 0 | 0 | 5,289 | 0 |
| Financing Cash Flow | $6,754 | $5,150 | $9,319 | $8,924 | $14,204 |
| Exchange Rate Effect | -24 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 51 | 106 | 1,166 | 14,179 | 17,392 |
| End Cash Position | 591 | 51 | 106 | 1,166 | 14,179 |
| Net Cash Flow | $540 | $-55 | $-1,060 | $-13,013 | $-3,213 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,190 | -5,205 | -10,348 | -21,937 | -17,410 |
| Capital Expenditure | N/A | N/A | -30 | N/A | -6 |
| Free Cash Flow | -6,190 | -5,205 | -10,379 | -21,937 | -17,416 |